{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:07:51Z","timestamp":1793333271281,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118491","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T22:09:20Z","timestamp":1756418960000},"page":"118491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Phase I study of intraperitoneal irinotecan with systemic capecitabine and oxaliplatin for patients with gastric peritoneal metastases"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-9093","authenticated-orcid":false,"given":"Niels A.D.","family":"Guchelaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0911-8905","authenticated-orcid":false,"given":"Marion W.","family":"Tops-Welten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-7819","authenticated-orcid":false,"given":"Pieter C.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo J.","family":"Noordman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd M.","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grard A.P.","family":"Nieuwenhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1991-4806","authenticated-orcid":false,"given":"Micha J.","family":"de Neijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9513-7126","authenticated-orcid":false,"given":"Irene E.G.","family":"van Hellemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha D.P.","family":"Luyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace H.J.T.","family":"De Hingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5193-0820","authenticated-orcid":false,"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas P.L.","family":"Wijnhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118491_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"32","key":"10.1016\/j.biopha.2025.118491_bib2","doi-asserted-by":"crossref","first-page":"52307","DOI":"10.18632\/oncotarget.10740","article-title":"Metastatic spread in patients with gastric cancer","volume":"7","author":"Riihim\u00e4ki","year":"2016","journal-title":"Oncotarget"},{"issue":"10251","key":"10.1016\/j.biopha.2025.118491_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.biopha.2025.118491_bib4","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.3390\/jcm10214882","article-title":"The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival","volume":"10","author":"Rijken","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118491_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118491_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10120-013-0306-2","article-title":"Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy","volume":"17","author":"Lee","year":"2014","journal-title":"Gastric Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2025.118491_bib7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118491_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.6004\/jnccn.2024.7013","article-title":"Systemic treatment strategies and outcomes of patients with synchronous peritoneal metastases of gastric origin: a nationwide Population-Based study","volume":"22","author":"Guchelaar","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"4","key":"10.1016\/j.biopha.2025.118491_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","article-title":"Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort","volume":"24","author":"Koemans","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.biopha.2025.118491_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103109","article-title":"The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study","volume":"81","author":"Guchelaar","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.biopha.2025.118491_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-plasma barrier","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118491_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41572-021-00326-6","article-title":"Primary and metastatic peritoneal surface malignancies","volume":"7","author":"Cort\u00e9s-Guiral","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.biopha.2025.118491_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","article-title":"Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies","volume":"83","author":"Guchelaar","year":"2023","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.biopha.2025.118491_bib14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/bjs.7586","article-title":"Systematic review of intraperitoneal chemotherapy for gastric cancer","volume":"98","author":"Matharu","year":"2011","journal-title":"Br. J. Surg."},{"issue":"13","key":"10.1016\/j.biopha.2025.118491_bib15","doi-asserted-by":"crossref","first-page":"8549","DOI":"10.1245\/s10434-024-16142-7","article-title":"Survival outcomes of cytoreductive surgery with HIPEC in gastric adenocarcinoma: a national cancer database study","volume":"31","author":"Khomiak","year":"2024","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118491_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jso.22017","article-title":"Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity","volume":"104","author":"Gill","year":"2011","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118491_bib17","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)","volume":"19","author":"Koemans","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118491_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae116","article-title":"Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis","volume":"111","author":"Guchelaar","year":"2024","journal-title":"Br. J. Surg."},{"issue":"1","key":"10.1016\/j.biopha.2025.118491_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis","volume":"20","author":"Kobayashi","year":"2017","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118491_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1078155213506244","article-title":"Intraperitoneal chemotherapy: rationale, applications, and limitations","volume":"20","author":"Al-Quteimat","year":"2014","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"7","key":"10.1016\/j.biopha.2025.118491_bib21","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","article-title":"Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases","volume":"28","author":"Saito","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118491_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118491_bib23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1245\/s10434-023-14240-6","article-title":"Phase II study of intraperitoneal administration of paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis","volume":"31","author":"Kobayashi","year":"2024","journal-title":"Ann. Surg. Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2025.118491_bib24","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: Phoenix-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4_","key":"10.1016\/j.biopha.2025.118491_bib25","first-page":"327","article-title":"Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: results from the multicenter, randomized, phase 3 DRAGON-01 trial","volume":"43","author":"Chao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118491_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev-med-081117-043436","article-title":"Gastric cancer etiology and management in Asia and the west","volume":"70","author":"Russo","year":"2019","journal-title":"Annu Rev. Med"},{"issue":"3","key":"10.1016\/j.biopha.2025.118491_bib27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1055-3207(03)00033-4","article-title":"Pharmacology of intraperitoneal CPT-11","volume":"12","author":"Matsui","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"10184","key":"10.1016\/j.biopha.2025.118491_bib28","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2025.118491_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000337400","article-title":"The impact of cross-resistance between paclitaxel and docetaxel for metastatic gastric cancer","volume":"35","author":"Shimura","year":"2012","journal-title":"Onkologie"},{"issue":"1","key":"10.1016\/j.biopha.2025.118491_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.131","article-title":"Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation","volume":"49","author":"Aldonza","year":"2017","journal-title":"Exp. Mol. Med"},{"issue":"35","key":"10.1016\/j.biopha.2025.118491_bib31","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.biopha.2025.118491_bib32","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1016\/j.ejca.2010.07.002","article-title":"Dose-escalation models for combination phase I trials in oncology","volume":"46","author":"Hamberg","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"27","key":"10.1016\/j.biopha.2025.118491_bib33","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2009.23.6703","article-title":"Phase I drug combination trial design: walking the tightrope","volume":"27","author":"Hamberg","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118491_bib34","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Health; [updated November 27, 2017. Available from: \u3008https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2025.118491_bib35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N. Engl. J. Med"},{"issue":"10294","key":"10.1016\/j.biopha.2025.118491_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.biopha.2025.118491_bib37","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118491_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00280-010-1272-6","article-title":"Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding","volume":"67","author":"Choi","year":"2011","journal-title":"Cancer Chemother. Pharm."},{"issue":"8","key":"10.1016\/j.biopha.2025.118491_bib39","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamaoncol.2020.2020","article-title":"FOLFIRINOX for the treatment of advanced gastroesophageal cancers: a phase 2 nonrandomized clinical trial","volume":"6","author":"Park","year":"2020","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118491_bib40","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/bjs\/znad228","article-title":"Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases","volume":"110","author":"van Eerden","year":"2023","journal-title":"Br. J. Surg."},{"issue":"12","key":"10.1016\/j.biopha.2025.118491_bib41","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1016\/j.ejmech.2010.09.023","article-title":"Synthesis and antitumor activity of novel benzimidazole-5-carboxylic acid derivatives and their transition metal complexes as topoisomerease II inhibitors","volume":"45","author":"Galal","year":"2010","journal-title":"Eur. J. Med Chem."},{"issue":"6","key":"10.1016\/j.biopha.2025.118491_bib42","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/psp4.13136","article-title":"Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin","volume":"13","author":"Rietveld","year":"2024","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"issue":"11","key":"10.1016\/j.biopha.2025.118491_bib43","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jjco\/hys129","article-title":"Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis","volume":"42","author":"Emoto","year":"2012","journal-title":"Jpn J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118491_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","article-title":"Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification","volume":"19","author":"Yoshida","year":"2016","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118491_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00432-007-0268-z","article-title":"Palliative gastrectomy and chemotherapy for stage IV gastric cancer","volume":"134","author":"Lin","year":"2008","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"17_","key":"10.1016\/j.biopha.2025.118491_bib46","volume":"42","author":"Salah-Eddin","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T02:46:58Z","timestamp":1760582818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225006857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"alternative-id":["S0753332225006857"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118491","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of intraperitoneal irinotecan with systemic capecitabine and oxaliplatin for patients with gastric peritoneal metastases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118491"}}